Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.51
-0.41 (-5.92%)
May 18, 2026, 4:00 PM EDT - Market closed
Solid Biosciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Solid Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 161.14% higher than the current stock price, while the lowest is $11 (+68.97%) and the highest is $26 (+299.39%).
Price Target: $17 (+161.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Solid Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $16 | Buy | Reiterates | $16 | +145.78% | May 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $17 → $16 | Buy | Maintains | $17 → $16 | +145.78% | May 13, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $17 → $18 | Buy | Maintains | $17 → $18 | +176.50% | May 13, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +84.33% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +207.22% | Mar 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
15.07M
EPS This Year
-1.82
from -1.99
EPS Next Year
-1.93
from -1.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 86.3M | ||||||
| Avg | n/a | 15.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.45 | -1.43 | ||||||
| Avg | -1.82 | -1.93 | ||||||
| Low | -2.14 | -2.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.